Welcome to Conformetrix
Conformetrix is a drug discovery company at the cutting-edge of ligand-based design. We develop new drugs by copying the templates provided by other bioactive ligands.
Our platform technology is a
powerful set of analytical tools that
can record the dynamic range of motion that molecules explore in
solution with extremely high precision. We call this data a
molecules' 4D-structure. By
analysing this structure we can
identify the bioactive shape of any optimised ligand. This is
a
true world first. It finally realises an entirely new and
complementary strategy to high-throughput screening that works for any
disease target.
Our unique competitive
advantage is in being able to copy Mother
Nature’s own "blockbuster blueprints": the peptide
hormones and other natural signalling molecules that regulate
the
human body's functions. These ligands have been
optimised over millions of years of evolution to be
highly
potent yet highly target-specific - the perfect profile for a
therapeutic drug.
April 2010
Meet Conformetrix! We will next be attending the BIO International Conference in Chicago (2-6 May 2010).
March 2010
Conformetrix CEO Dr Andrew Almond presents the company's platform technology at the prestigious annual American Chemical Society conference in San Francisco.
February 2010
Conformetrix validates its ligand-based drug discovery platform by identifying novel hit scaffolds for both ion-channel and GPCR targets.
November 2009
Conformetrix receives the first investment from Aquarius Equity Partners' new Origin Fund.